title: Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q.
abstract: OBJECTIVE
  Splenic marginal zone B-cell lymphoma (SMZBCL) has clinical, immunophenotypic and histologic features distinct from other B-cell malignancies, but few chromosome studies have been previously reported. In the present study we performed conventional cytogenetics and in situ hybridization studies in 47 patients with SMZBCL.
  
  
  METHODS
  We studied 47 cases of splenic marginal zone B-cell lymphoma combining conventional cytogenetics and in situ hybridization (ISH) techniques using centromeric probes (chromosomes 3 and 12), locus specific probes (7q31 and 17p13) and cross-species color banding fluorescent ISH probes (RxFISH). The diagnosis of SMZBCL was ascertained in all cases after studying, morphologically and immunologically, peripheral blood and splenectomy specimens.
  
  
  RESULTS
  A clonal chromosome abnormality detected by conventional cytogenetics and/or FISH was found in 33/47 patients (70%) being identified in 18 (18/33, 55%) as a complex abnormality. The most frequently recurrent abnormalities were: gain of 3q (10 cases), del(7q) (12 cases), and involvement of chromosomes 1, 8 and 14. No patient showed translocation t(11;14) (q13;q32) or t(14;18) (q21;q32). Trisomy 3 was detected in eight cases (8/47, 17%). Two novel cytogenetic abnormalities involving 14q32, t(6;14)(p12;q32) and t(10;14) (q24;q32) were reported. Deletion of 17p13 (P53) was observed by FISH in one case. Only one patient showed a gain of 3q or trisomy 3 and deletion 7q in the same karyotype.
  
  
  CONCLUSIONS
  Our findings support the interpretation that two forms of SMZBCL could be considered, one with gain of 3q and the other with deletions at 7q.
authors.affiliation: Laboratori de Citologia Hematològica, Laboratori de Referència de Catalunya, Departament de Patologia, Hospital del Mar, IMAS, IMIM, Passeig Maritim, 25-29, 08003 Barcelona, Spain. e0037@imas.imim.es
authors.forename: F
authors.initials: F
authors.lastname: Solé
authors.forename: M
authors.initials: M
authors.lastname: Salido
authors.forename: B
authors.initials: B
authors.lastname: Espinet
authors.forename: J L
authors.initials: JL
authors.lastname: Garcia
authors.forename: J A
authors.initials: JA
authors.lastname: Martinez Climent
authors.forename: I
authors.initials: I
authors.lastname: Granada
authors.forename: J M
authors.initials: JM
authors.lastname: Hernández
authors.forename: I
authors.initials: I
authors.lastname: Benet
authors.forename: M A
authors.initials: MA
authors.lastname: Piris
authors.forename: M
authors.initials: M
authors.lastname: Mollejo
authors.forename: P
authors.initials: P
authors.lastname: Martinez
authors.forename: T
authors.initials: T
authors.lastname: Vallespí
authors.forename: A
authors.initials: A
authors.lastname: Domingo
authors.forename: S
authors.initials: S
authors.lastname: Serrano
authors.forename: S
authors.initials: S
authors.lastname: Woessner
authors.forename: L
authors.initials: L
authors.lastname: Florensa
mesh_terms: D002869:Chromosome Aberrations; D020732:Cytogenetic Analysis; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000235:genetics* / Q000473:pathology; D008297:Male; D013160:Splenic Neoplasms / Q000235:genetics / Q000473:pathology*